Neoantigen-based cancer immunotherapy
- 1 July 2016
- journal article
- review article
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 4 (14) , 262
Abstract
Emerging clinical evidence on the role of the antitumor activity of the immune system has generated great interest in immunotherapy in all cancer types. Recent clinical data clearly demonstrated that human tumor cells express antigenic peptides (epitopes) that can be recognized by autologous tumor-specific T cells and that enhancement of such immune reactivity can potentially lead to cancer control and cancer regression in patients with advanced disease. However, in most cases, it is unclear which tumor antigens (Ags) mediated cancer regression. Mounting evidence indicates that numerous endogenous mutated cancer proteins, a hallmark of tumor cells, can be processed into peptides and presented on the surface of tumor cells, leading to their immune recognition in vivo as “non-self” or foreign. Massively parallel sequencing has now overcome the challenge of rapidly identifying the comprehensive mutational spectrum of individual tumors (i.e., the “mutanome”) and current technologies, as well as computational tools, have emerged that allow the identification of private epitopes derived from their mutanome and called neoantigens (neoAgs). On this basis, both CD4+ and CD8+ neoantigen-specific T cells have been identified in multiple human cancers and shown to be associated with a favorable clinical outcome. Notably, emerging data also indicate that neoantigen recognition represents a major factor in the activity of clinical immunotherapies. In the post-genome era, the mutanome holds promise as a long-awaited ‘gold mine’ for the discovery of unique cancer cell targets, which are exclusively tumor-specific and unlikely to drive immune tolerance, hence offering the chance for highly promising clinical programs of cancer immunotherapy.Keywords
This publication has 46 references indexed in Scilit:
- Mutanome directed cancer immunotherapyCurrent Opinion in Immunology, 2016
- Targeting the undruggable: immunotherapy meets personalized oncology in the genomic eraAnnals of Oncology, 2015
- High burden and pervasive positive selection of somatic mutations in normal human skinScience, 2015
- Mutant MHC class II epitopes drive therapeutic immune responses to cancerNature, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial CancerScience, 2014
- Expression of tumour-specific antigens underlies cancer immunoeditingNature, 2012
- Cloning Genes Encoding MHC Class II-Restricted Antigens: Mutated CDC27 as a Tumor AntigenScience, 1999
- A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human MelanomaScience, 1995
- Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide.Journal of Experimental Medicine, 1990